AASLD (2018) American Association for Study of Liver Diseases: HCV guidance: recommendations for testing, managing, and treating hepatitis C. https://www.hcvguidelines.org. Accessed 18 Feb 2020

Alberti A, Lacoin L, Morais E, Lefevre C, Abogunrin S, Iheanacho I et al (2016) Literature review of the distribution of hepatitis C virus genotypes across Europe. J Med Virol 88(12):2157–2169

Article  Google Scholar 

Baden R, Rockstroh JK, Buti M (2014) Natural history and management of hepatitis C: does sex play a role? J Inf Dis 209(Suppl 3):S81–S85

CAS  Article  Google Scholar 

Cavalcante LN, Lyra AC (2015) Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol 7(12):1617–1631

Article  Google Scholar 

Chlibek R, Smetana J, Sosovickova R, Gal P, Dite P, Stepanova V, Pliskova L, Plisek S et al (2017) Prevalence of hepatitis C virus in adult population in the Czech Republic: time for birth cohort screening. PLoS ONE 12(4):e0175525

Article  Google Scholar 

Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Hepatitis Interventional Therapy Group (1989) Treatment of chronic hepatitis C with recombinant interferon alpha. N Engl J Med 321:1501–1506

CAS  Article  Google Scholar 

EASL (2018) European Association for the Study of the Liver: EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69:461–511

Article  Google Scholar 

ECDC (2018) European Centre for Disease Prevention and Control: Hepatitis C. Annual epidemiological report for 2017. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-hepatitis-C.pdf. Accessed 20 Feb 2020

Erman A, Krahn MD, Hansen T, Wong J, Bielecki JM, Feld JJ, Wong WWL, Grootendorst P, Thein HH (2019) Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. BMJ Open 9:e027491

Article  Google Scholar 

Fathi H, Clark A, Hill NR, Dusheiko G (2017) Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic Review. BMC Infect Dis 17:722

Article  Google Scholar 

Flisiak R, Urbanek P, Rokusz L, Oltman M, Makara M, Janicko M (2016) New therapeutic options for HCV in Central Europe. Clin Exper Hepatol 1:7–11

Article  Google Scholar 

Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM (2001) Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatol 34:809–816

CAS  Article  Google Scholar 

Jimenez-Mendez R, Uribe-Salas F, López-Guillen P, Cisneros-Garza L, Castañeda-Hernandez G (2010) Distribution of HCV genotypes and HCV RNA viral load in different regions of Mexico. Ann Hepatol 9:33–39

Article  Google Scholar 

Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB (2014) HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 60(1):98–105

CAS  Article  Google Scholar 

Madalinski K, Zakrzewska K, Kolakowska A, Godzik P (2015) Epidemiology of HCV infection in Central and Eastern Europe. Przegl Epidemiol 69(3):459–464

PubMed  Google Scholar 

Mangia A, De Ledinghen V, Bailly F, Brahm J, Keiss J, Valantinas J, Rasmann N, Messinger D, Tatsch F, Bakalos G, Foster GR, Gen-C study Group (2016) IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. SpringerPlus 5:1990

Article  Google Scholar 

Mendes LC, Stucchi RSB, Vigiani AG (2018) Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies. Hepatic Med Evid Res 2018(10):13–22

Article  Google Scholar 

Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61(1):77–87

Article  Google Scholar 

Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y (2013) Eradication of hepatitis c virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158:329–337

Article  Google Scholar 

Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U (2009) HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbiditiy, and mortality—review. BMC Public Health 9:34

Article  Google Scholar 

Nemecek V, Castkova J, Fritz P, Linhartová A, Svandová E, Srámová H, Kríz B (2003) The 2001 serological survey in the Czech Republic—viral hepatitis. Cent Eur J Public Health 11:S54–S61

PubMed  Google Scholar 

Paralicova Z, Kristian P, Schreter I (2009) Epidemiological survey of hepatitis C at the Clinic of Infectology and Travel Medicine in Kosice. Epidemiol Mikrobiol Immunol 58(4):158–162

CAS  Google Scholar 

Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C (2016) Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 22:7824–7840

Article  Google Scholar 

Petruzziello A, Sabatino R, Loquercio G, Guzzo A, Di Capua L, Labonia F, Cozzolino A, Azzaro R, Botti G (2019) Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy. PLoS ONE 14(2):e0212033

CAS  Article  Google Scholar 

Polaris Observatory HCV Collaborators (2016) Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2:161–176

Google Scholar 

Popping S, Cento V, Garcia F, Ceccherini-Silberstein F, Seguin-Devaux C, Vijver DA, Boucher CA (2018) The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C. J Virus Eradic 4:179–181

Article  Google Scholar 

Poynard T, Macellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352(9138):1426–1432

CAS  Article  Google Scholar 

Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R (2013) Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 57(6):2164–2170

Article  Google Scholar 

Sandmann L, Schulte B, Manns MP, Maasoumy B (2019) Treatment of chronic hepatitis C: efficacy, side effects and complications. Visc Med 35:161–170

Article  Google Scholar 

Schreter I, Kristian P, Klement C, Kohútová D, Jarcuska P, Madarová L, Avdicová M, Máderová E (2007) Prevalence of hepatitis C virus infection in Slovakia. Klin Mikrobiol Infekc Lek 13(2):54–58 (in Slovak)

CAS  PubMed  Google Scholar 

Urbanek P, Kristian P, Makara M, Hunyady B, Tomasiewicz K (2016) Epidemiology of HCV infection in the Central European region. Clin Exper Hepatol 1:2–6

Article  Google Scholar 

Villa E, Vukotic R, Cammà C, Petta S, Di Leo A et al (2012) Reproductive status is associated with the severity of fibrosis in women with hepatitis C. PLoS ONE 7(9):e44624

CAS  Article  Google Scholar 

WHO (2016) World Health Organization: Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. http://www.who.int/hepatitis/en/. Accessed 20 Feb 2020

WHO (2017a) World Health Organization: Hepatitis C in the WHO European Region. http://www.euro.who.int/__data/assets/pdf_file/0010/283357/fact-sheet-en-hep-c-edited.pdf. Accessed 20 Feb 2020

WHO (2019a) World Health Organization: Hepatitis C. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed 20 Feb 2020

WHO (2019b) World Health Organization: consolidated strategic information guidelines for viral hepatitis. Planning and tracking progress towards elimination. http://www.euro.who.int/en/health-topics/communicable-diseases/hepatitis/publications/2019/consolidated-strategic-information-guidelines-for-viral-hepatitis-planning-and-tracking-progress-towards-elimination-2019. Accessed 20 Feb 2020